
JFrog Ltd. (FROG) Q2 2026 Earnings Call Transcript
JFrog Ltd. (FROG) Q2 2026 Earnings Call Transcript
تابع أحدث الأخبار المالية والاقتصادية وتحديثات الأسواق والتقارير والتحليلات على PipVero.

JFrog Ltd. (FROG) Q2 2026 Earnings Call Transcript

JD Sports Fashion PLC (LSE:JD., OTC:JDSPY) has appointed Peter Agnefjäll as chair of the board with effect from 1 September 2026.

Genel Energy PLC (LSE:GENL, FRA:4VL, OTC:GEGYY) has rejected a £202 million cash approach from DNO, its Norwegian rival in the Kurdistan region of Iraq. DNO has taken the proposal public after being rebuffed, a move that raises pressure on the Genel board to open talks.

TechTarget, Inc. (TTGT) Q2 2026 Earnings Call Transcript

Expensify, Inc. (EXFY) Q2 2026 Earnings Call Transcript

A new paper finds a weak correlation between gold and inflation.

Oxford BioMedica PLC (LSE:OXB), the cell and gene therapy manufacturer, has cut its revenue guidance for 2026 after clients deferred orders and a US site took longer than expected to come online. The company now expects full-year revenues of £180 million to £200 million.

Israel-based Ratio Petroleum Energy raised its takeover bid for Pharos Energy to about £146.4 million ($196.97 million) on Friday, outbidding rival oil producer Serica Energy and winning back the board's recommendation.

Ocugen NASDAQ: OCGN said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the program.

OmniAb NASDAQ: OABI reported higher second-quarter revenue and a narrower net loss as milestone payments from partner programs increased, while the company raised its full-year 2026 revenue and year-end cash outlook.

Nova NASDAQ: NVMI reported record second-quarter revenue of $255 million, up 8% sequentially and 16% from a year earlier, as demand increased across its semiconductor process-control portfolio. The company said revenue reached the high end of its guidance range, while non-GAAP diluted earnings per share of $2.51 exceeded the high end of its outlook.

Novavax NASDAQ: NVAX reported second-quarter 2026 revenue of $57 million and a net loss of $53 million, while highlighting progress in its Sanofi partnership, expanding use of its Matrix-M adjuvant platform and continued cost reductions.

Natera NASDAQ: NTRA reported second-quarter 2026 revenue of approximately $753 million, up about 38% from a year earlier, as record testing volumes and higher average selling prices supported growth across its oncology, women's health and organ health businesses.

Intellia Therapeutics NASDAQ: NTLA said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis.

NETGEAR NASDAQ: NTGR reported second-quarter 2026 revenue of $168.6 million, down 1.2% from a year earlier but up 6.1% sequentially, as growth in its enterprise segment offset continued pressure in consumer products. The company said revenue and non-GAAP operating margin exceeded the high end of its guidance range.